ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintSite TitleTitle ChevronIcon Twitter
Pharmaceuticals

Taiwan approves Gilead's remdesivir to treat COVID-19

Authorities say conditions met for use in patients with 'severe' infections

There is currently no approved treatment or vaccine for COVID-19, but EU countries are already administering remdesivir to patients under compassionate use rules.   © Reuters

TAIPEI (Reuters) -- Taiwan's government said on Saturday it had approved Gilead Sciences' potential COVID-19 treatment, remdesivir, to treat the illness caused by the novel coronavirus.

Governments are racing to bolster supplies of remdesivir, which U.S. regulators this month approved for emergency use. California-based Gilead has said it will donate 1.5 million doses of remdesivir, enough to treat at least 140,000 patients, to combat the global pandemic.

Taiwan's Central Epidemic Command Centre said the Taiwan Food and Drug Administration took into account "the fact that the efficacy and safety of remdesivir has been supported by preliminary evidence" and its use is being approved by other countries.

On that basis, the centre said the conditions had been met for approval of the drug for use in patients with "severe" COVID-19 infection.

Taiwan has been successful at preventing the coronavirus from spreading, thanks to early detection and prevention work and a first rate public health system.

It has recorded 442 cases and only 7 deaths. The vast majority of people have recovered, with just 14 active cases.

There is currently no approved medication or vaccine for COVID-19, but EU countries are already administering remdesivir to patients under compassionate use rules.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends July 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media